Genes, p16
-
Subject Areas on Research
- A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution.
- A common variant on chromosome 9p21 affects the risk of myocardial infarction.
- Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
- Analysis of 60 reported glioma risk SNPs replicates published GWAS findings but fails to replicate associations from published candidate-gene studies.
- CDKN2A promoter methylation in gastric adenocarcinomas: clinical variables.
- Comprehensive genomic characterization of squamous cell lung cancers.
- Correspondence re: Zheng et al, Haplotype of two variants in p16 (CDKN2/MTS-1/INK4a) exon 3 and risk of squamous cell carcinoma of the head and neck: a case-control study. 11: 640-645, 2002.
- Deletions and point mutations of p16,p15 gene in primary tumors and tumor cell lines.
- Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants.
- Epstein-Barr virus in gastric adenocarcinomas: association with ethnicity and CDKN2A promoter methylation.
- Haplotypes of two variants in p16 (CDKN2/MTS-1/INK4a) exon 3 and risk of squamous cell carcinoma of the head and neck: a case-control study.
- Immunohistochemical expression of p16 and Ki-67 correlates with degree of anal intraepithelial neoplasia.
- Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies.
- Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression.
- K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking.
- Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome.
- Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
- Loss of tumor suppressor gene expression in high-grade but not low-grade non-Hodgkin's lymphomas.
- Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
- Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.
- Molecular genetic parameters in pathogenesis and prognosis of testicular germ cell tumors.
- Morphologic and molecular genetic aspects of oligodendroglial neoplasms.
- Squamous cell carcinoma of the oral cavity often overexpresses p16 but is rarely driven by human papillomavirus.
- Survey of familial glioma and role of germline p16INK4A/p14ARF and p53 mutation.
- The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
- The potent antitumor effects of combined p16 gene and GM-CSF gene therapy through efficient induction of antitumor immunity.
- p16 Improves interobserver agreement in diagnosis of anal intraepithelial neoplasia.
- p16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis.
-
Keywords of People
- Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology